Skoura Evangelia, Datseris Ioannis E, Exarhos Dimitrios, Chatziioannou Sophia, Oikonomopoulos Georgios, Samartzis Alexandros, Giannopoulou Chariklia, Syrigos Konstantinos N
Departments of Nuclear Medicine, Evangelismos General Hospital, Athens, Greece.
Oncol Lett. 2013 May;5(5):1687-1693. doi: 10.3892/ol.2013.1257. Epub 2013 Mar 14.
[F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) has been reported to have a low sensitivity in the initial diagnosis of bronchoalveolar carcinoma (BAC) due to BAC's low metabolic activity. The aim of this study was to assess the value of [F]FDG-PET/CT in the detection of BAC recurrence. Between February 2007 and September 2011, the [F]FDG-PET/CT scans that were performed on patients with known, histologically proven BAC were studied. A total of 24 [F]FDG-PET/CT scans were performed in 22 patients, including 16 males and 6 females, with a mean age of 65±9 years. Among the scans, 15 were performed to assess for possible recurrence with equivocal findings in conventional imaging methods and 9 for restaging post-therapy. In all cases conventional imaging studies (CT and MRI) were performed 5-30 days prior to PET/CT. Among the 24 [F]FDG-PET/CT scans, 18 were positive and 6 negative. Among the 15 [F]FDG-PET/CT scans performed for suspected recurrence, 34 lesions were detected and the mean maximum standardized uptake value (SUVmax) was 6.8±3.26. In nine scans, upstaging was observed, while two were in agreement with the findings of the conventional modalities. A greater number of lesions were detected in two scans and fewer lesions were detected in one, with no change in staging. Only one scan was negative. By contrast, in patients examined for restaging, there were only five lesions with a mean SUVmax of 4.86±3.18. Agreement between the findings of [F]FDG-PET/CT and the conventional modalities was observed in 8 out of 9 cases. Although [F]FDG-PET/CT has been reported to have a low sensitivity in the initial diagnosis of BAC, the present results indicate that when there is recurrence, the lesions become [F]FDG avid. [F]FDG-PET/CT may provide further information in patients evaluated for recurrence and thus improve patient management.
[F]氟代脱氧葡萄糖（FDG）正电子发射断层扫描（PET）/计算机断层扫描（CT）据报道在细支气管肺泡癌（BAC）的初始诊断中敏感性较低，因为BAC的代谢活性较低。本研究的目的是评估[F]FDG-PET/CT在检测BAC复发中的价值。在2007年2月至2011年9月期间，对已知经组织学证实为BAC的患者进行的[F]FDG-PET/CT扫描进行了研究。共对22例患者进行了24次[F]FDG-PET/CT扫描，其中男性16例，女性6例，平均年龄65±9岁。在这些扫描中，15次是为了评估传统成像方法中可疑发现的可能复发情况，9次是为了治疗后重新分期。在所有病例中，传统成像研究（CT和MRI）在PET/CT前5 - 30天进行。在24次[F]FDG-PET/CT扫描中，18次为阳性，6次为阴性。在为疑似复发进行的15次[F]FDG-PET/CT扫描中，检测到34个病灶，平均最大标准化摄取值（SUVmax）为6.8±3.26。在9次扫描中，发现分期上调，而2次与传统检查结果一致。在2次扫描中检测到的病灶数量更多，1次扫描中检测到的病灶数量更少，分期无变化。只有1次扫描为阴性。相比之下，在为重新分期而检查的患者中，只有5个病灶，平均SUVmax为4.86±3.18。9例中有8例观察到[F]FDG-PET/CT结果与传统检查结果一致。尽管[F]FDG-PET/CT据报道在BAC的初始诊断中敏感性较低，但目前的结果表明，当出现复发时，病灶会变得对[F]FDG摄取增加。[F]FDG-PET/CT可能为评估复发的患者提供更多信息，从而改善患者管理。
